METEOSIM 50CPR MAST 40MG

METEOSIM 40 MG COMPRESSE MASTICAL

active ingredients

Each tablet contains: Active ingredient: symeticons 40 mg. Excipient with known effects: lactose. For the full list of excipients, see paragraph 6.1.

Excellent

Sodium saccharin, alginic acid, lactose, sodium bicarbonate, povidone, calcium silicate monohydrate, methylcellulose.

Therapeutic indications

Syntomatic treatment of gastro-enteric meteorism and adult aerophagia

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.

Population

Population: Adults: 4 tablets daily (2 at the end of each main meal). Method of administration: Tablets must be chewed.

Conservation

Store the medicine in the original packaging protected from light and moisture.

Warnings

Do not exceed the recommended doses. After a short period of treatment without appreciable results consult your doctor. The drug contains lactose is therefore not suitable for individuals with lactase deficiency, galactosemia or glucose/galactose disease syndrome.

Interactions

No known or reported interactions with other drugs

Effects

Undesirable effects due to METEOSIM have not been highlighted. Reporting of side effects. If you show any unwanted effect, including those not listed in this sheet, please refer to your doctor or pharmacist. You can also report the side effects directly through the national reporting system at the address www.agenziafarmaco.gov.it/it/responsabili. Reporting the side effects you may contribute to providing more information on the safety of this medicine.

Overdosing

Overdose phenomena have not been reported with the use of METEOSIM.

Pregnancy:

There is no adequate data on the use of METEOSIM in pregnant women, therefore it should not be used in pregnancy unless a real necessity and after the assessment of the risk/benefit by the doctor.

Nursing:

It is not known whether symeticons are excreted in breast milk. The excretion of symeticons in breast milk was not studied in animals. The decision whether to continue/interrupt treatment based on symeticons should be taken taking into consideration the benefit of breastfeeding for the newborn and the treatment based on symeticons for women.

Source: Farmadati